The U.S. Food and Drug Administration (FDA) has approved the usage of the Guardant360 CDx and FoundationOne Liquid CDx liquid biopsy tests for a number of solid tumors. The biopsies will be conducted via the blood, hence making them less painful, and more accessible. Additionally, since tumors change over time, the liquid biopsy tests can be used shortly after a treatment has started, to easily detect the efficacy of the treatment. Another goal of these new liquid biopsy tests will be to detect cancer much earlier on, reducing severe long term health effects.
Read more here.
More on: News Regulatory